Literature DB >> 3598359

Squamous cell hyperplasia of the larynx (a clinical follow-up study).

P O Kalter, H Lubsen, J F Delemarre, G B Snow.   

Abstract

According to Kleinsasser's classification 200 patients with squamous cell hyperplasia, seen between 1963-1981, were reviewed histologically. The untreated patients (47 per cent) have been analysed for the incidence of malignant change and the patients with Class III lesions (carcinoma in situ) who were treated, were analysed for response to treatment. The mean follow-up period was 8.4 years. Only two of the 38 initially untreated patients of Class I (simple squamous cell hyperplasia) developed an invasive carcinoma. In Class II (hyperplasia with atypia), of 62 patients who were not treated initially, 17 developed a laryngeal squamous cell carcinoma later. Only six patients of Class III did not receive any treatment initially, and one of these progressed to invasive carcinoma. Almost all other patients with carcinoma in situ (Class III) were irradiated. In these patients no evidence of local recurrence was found.

Entities:  

Mesh:

Year:  1987        PMID: 3598359     DOI: 10.1017/s0022215100102282

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  4 in total

1.  The impact of laryngeal dysplasia on the development of laryngeal squamous cell carcinoma.

Authors:  J C Luers; K Sircar; U Drebber; D Beutner
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-08-30       Impact factor: 2.503

Review 2.  Management of laryngeal dysplasia: a review.

Authors:  Maziar Sadri; Jeremy McMahon; Andrew Parker
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-07-06       Impact factor: 2.503

3.  Benign keratoma of the vocal cords.

Authors:  T Kimmich; O Kleinsasser
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

Review 4.  Developing Classifications of Laryngeal Dysplasia: The Historical Basis.

Authors:  Henrik Hellquist; Alfio Ferlito; Antti A Mäkitie; Lester D R Thompson; Justin A Bishop; Abbas Agaimy; Juan C Hernandez-Prera; Douglas R Gnepp; Stefan M Willems; Pieter J Slootweg; Alessandra Rinaldo
Journal:  Adv Ther       Date:  2020-04-23       Impact factor: 3.845

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.